CytRx Corporation (CYTR) Receives Recommendation From Data Safety Monitoring Committee to Complete International Phase 2b Trial With Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
5/6/2013 10:08:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced that the independent Data Safety Monitoring Committee (DSMC) overseeing the Company’s international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion. This Phase 2b trial allows for a head-to-head clinical comparison of the commonly used chemotherapeutic agent doxorubicin with aldoxorubicin, CytRx’s tumor-targeting doxorubicin conjugate. Doxorubicin is dose-limited at a level below its maximum anti-tumor capabilities due to toxicity, including cardiotoxicity. Data from the Phase 2b trial is expected in the second half of 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by